Hydroxychloroquine for hospitalized patients with COVID19 [COVID-19]
Research type
Research Study
Full title
An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19
IRAS ID
282362
Contact name
Dinesh Saralaya
Contact email
Sponsor organisation
sanofi-aventis recherche & développement
Eudract number
2020-001270-29
Duration of Study in the UK
0 years, 2 months, 11 days
Research summary
This study is an adaptive, multi-national, multi-center, randomized, open-label, Phase 2/3 trial to evaluate the efficacy and safety of Hydroxychloroquine in addition to standard of care as compared to standard of care only in hospitalized adult patients with moderate to severe COVID-19.\nThere are currently no effective drugs for the treatment of patients with moderate to severe COVID-19. Investigations aiming to evaluate the safety and effectiveness of novel or repurposed medications in moderate to severe COVID-19 are needed to identify safe and effective agents that could help individuals and societies impacted by the SARS-CoV-2 pandemic.\n
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
20/NE/0108
Date of REC Opinion
2 Apr 2020
REC opinion
Further Information Favourable Opinion